nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoprolol—ABCB1—esophageal cancer	0.562	1	CbGaD
Metoprolol—SLC22A2—Cisplatin—esophageal cancer	0.146	0.695	CbGbCtD
Metoprolol—ABCB1—Cisplatin—esophageal cancer	0.0389	0.185	CbGbCtD
Metoprolol—ABCB1—Methotrexate—esophageal cancer	0.0253	0.12	CbGbCtD
Metoprolol—Hepatic cirrhosis—Methotrexate—esophageal cancer	0.004	0.0278	CcSEcCtD
Metoprolol—Skin lesion—Capecitabine—esophageal cancer	0.00395	0.0274	CcSEcCtD
Metoprolol—Coronary artery disease—Cisplatin—esophageal cancer	0.00354	0.0246	CcSEcCtD
Metoprolol—Dyspnoea exertional—Capecitabine—esophageal cancer	0.00341	0.0237	CcSEcCtD
Metoprolol—Obstructive airways disorder—Methotrexate—esophageal cancer	0.00338	0.0235	CcSEcCtD
Metoprolol—Rales—Capecitabine—esophageal cancer	0.00251	0.0174	CcSEcCtD
Metoprolol—Altered state of consciousness—Capecitabine—esophageal cancer	0.00223	0.0155	CcSEcCtD
Metoprolol—Peripheral coldness—Capecitabine—esophageal cancer	0.00217	0.015	CcSEcCtD
Metoprolol—Rales—Methotrexate—esophageal cancer	0.00187	0.013	CcSEcCtD
Metoprolol—Loss of libido—Methotrexate—esophageal cancer	0.00166	0.0115	CcSEcCtD
Metoprolol—Respiratory distress—Capecitabine—esophageal cancer	0.00162	0.0113	CcSEcCtD
Metoprolol—Chlorphenesin—CYP19A1—esophageal cancer	0.00159	0.423	CrCbGaD
Metoprolol—Blood triglycerides increased—Capecitabine—esophageal cancer	0.00157	0.0109	CcSEcCtD
Metoprolol—Hearing impaired—Cisplatin—esophageal cancer	0.00147	0.0102	CcSEcCtD
Metoprolol—Pain—Carboplatin—esophageal cancer	0.00145	0.0101	CcSEcCtD
Metoprolol—Throat sore—Capecitabine—esophageal cancer	0.00143	0.00993	CcSEcCtD
Metoprolol—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.00142	0.00984	CcSEcCtD
Metoprolol—Wheezing—Cisplatin—esophageal cancer	0.00136	0.00943	CcSEcCtD
Metoprolol—Body temperature increased—Carboplatin—esophageal cancer	0.00134	0.00933	CcSEcCtD
Metoprolol—Memory impairment—Capecitabine—esophageal cancer	0.00131	0.00912	CcSEcCtD
Metoprolol—Psoriasis—Methotrexate—esophageal cancer	0.00122	0.00848	CcSEcCtD
Metoprolol—Eye irritation—Capecitabine—esophageal cancer	0.00121	0.00838	CcSEcCtD
Metoprolol—Deafness—Cisplatin—esophageal cancer	0.00113	0.00788	CcSEcCtD
Metoprolol—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00113	0.00787	CcSEcCtD
Metoprolol—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00112	0.00777	CcSEcCtD
Metoprolol—Cyanosis—Methotrexate—esophageal cancer	0.00108	0.00753	CcSEcCtD
Metoprolol—Hearing impaired—Capecitabine—esophageal cancer	0.00108	0.00752	CcSEcCtD
Metoprolol—Amnesia—Cisplatin—esophageal cancer	0.00108	0.0075	CcSEcCtD
Metoprolol—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00104	0.00719	CcSEcCtD
Metoprolol—Depressed level of consciousness—Capecitabine—esophageal cancer	0.000996	0.00691	CcSEcCtD
Metoprolol—Dry eye—Capecitabine—esophageal cancer	0.000952	0.00661	CcSEcCtD
Metoprolol—Orthostatic hypotension—Cisplatin—esophageal cancer	0.000927	0.00644	CcSEcCtD
Metoprolol—Breast disorder—Cisplatin—esophageal cancer	0.000917	0.00637	CcSEcCtD
Metoprolol—Cramp muscle—Cisplatin—esophageal cancer	0.000914	0.00635	CcSEcCtD
Metoprolol—Mental disability—Capecitabine—esophageal cancer	0.000895	0.00621	CcSEcCtD
Metoprolol—Sleep disorder—Capecitabine—esophageal cancer	0.000865	0.006	CcSEcCtD
Metoprolol—Diabetes mellitus—Capecitabine—esophageal cancer	0.00086	0.00597	CcSEcCtD
Metoprolol—Hepatic function abnormal—Capecitabine—esophageal cancer	0.000856	0.00594	CcSEcCtD
Metoprolol—Sweating increased—Cisplatin—esophageal cancer	0.000855	0.00593	CcSEcCtD
Metoprolol—Photosensitivity—Capecitabine—esophageal cancer	0.000852	0.00592	CcSEcCtD
Metoprolol—Deafness—Capecitabine—esophageal cancer	0.000837	0.00581	CcSEcCtD
Metoprolol—Libido decreased—Capecitabine—esophageal cancer	0.000807	0.0056	CcSEcCtD
Metoprolol—Hot flush—Capecitabine—esophageal cancer	0.0008	0.00555	CcSEcCtD
Metoprolol—Amnesia—Capecitabine—esophageal cancer	0.000797	0.00553	CcSEcCtD
Metoprolol—Menopausal symptoms—Capecitabine—esophageal cancer	0.000793	0.00551	CcSEcCtD
Metoprolol—Arthritis—Capecitabine—esophageal cancer	0.00077	0.00534	CcSEcCtD
Metoprolol—Cardiac failure—Capecitabine—esophageal cancer	0.000767	0.00532	CcSEcCtD
Metoprolol—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000764	0.0053	CcSEcCtD
Metoprolol—Conjunctivitis—Cisplatin—esophageal cancer	0.00076	0.00528	CcSEcCtD
Metoprolol—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000742	0.00515	CcSEcCtD
Metoprolol—Depressed level of consciousness—Methotrexate—esophageal cancer	0.000741	0.00514	CcSEcCtD
Metoprolol—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00074	0.00514	CcSEcCtD
Metoprolol—Chlorphenesin—PTGS2—esophageal cancer	0.000732	0.194	CrCbGaD
Metoprolol—Bradycardia—Cisplatin—esophageal cancer	0.000715	0.00496	CcSEcCtD
Metoprolol—Cardiac arrest—Capecitabine—esophageal cancer	0.000712	0.00494	CcSEcCtD
Metoprolol—Mood swings—Capecitabine—esophageal cancer	0.000709	0.00492	CcSEcCtD
Metoprolol—Coma—Methotrexate—esophageal cancer	0.000701	0.00487	CcSEcCtD
Metoprolol—Liver function test abnormal—Capecitabine—esophageal cancer	0.000691	0.0048	CcSEcCtD
Metoprolol—Connective tissue disorder—Cisplatin—esophageal cancer	0.00069	0.00479	CcSEcCtD
Metoprolol—Abdominal pain upper—Capecitabine—esophageal cancer	0.000684	0.00474	CcSEcCtD
Metoprolol—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000684	0.00474	CcSEcCtD
Metoprolol—Visual impairment—Cisplatin—esophageal cancer	0.000677	0.0047	CcSEcCtD
Metoprolol—Breast disorder—Capecitabine—esophageal cancer	0.000676	0.00469	CcSEcCtD
Metoprolol—Eye disorder—Cisplatin—esophageal cancer	0.000656	0.00456	CcSEcCtD
Metoprolol—Tinnitus—Cisplatin—esophageal cancer	0.000655	0.00455	CcSEcCtD
Metoprolol—Cardiac disorder—Cisplatin—esophageal cancer	0.000652	0.00452	CcSEcCtD
Metoprolol—Diabetes mellitus—Methotrexate—esophageal cancer	0.000641	0.00445	CcSEcCtD
Metoprolol—Bronchospasm—Capecitabine—esophageal cancer	0.000636	0.00442	CcSEcCtD
Metoprolol—Photosensitivity—Methotrexate—esophageal cancer	0.000634	0.0044	CcSEcCtD
Metoprolol—Immune system disorder—Cisplatin—esophageal cancer	0.000634	0.0044	CcSEcCtD
Metoprolol—Mediastinal disorder—Cisplatin—esophageal cancer	0.000633	0.00439	CcSEcCtD
Metoprolol—Angina pectoris—Capecitabine—esophageal cancer	0.00063	0.00437	CcSEcCtD
Metoprolol—Sweating increased—Capecitabine—esophageal cancer	0.00063	0.00437	CcSEcCtD
Metoprolol—Arrhythmia—Cisplatin—esophageal cancer	0.000627	0.00436	CcSEcCtD
Metoprolol—Atenolol—ABCB1—esophageal cancer	0.000622	0.165	CrCbGaD
Metoprolol—Alopecia—Cisplatin—esophageal cancer	0.000621	0.00431	CcSEcCtD
Metoprolol—Flatulence—Cisplatin—esophageal cancer	0.000602	0.00418	CcSEcCtD
Metoprolol—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00059	0.0041	CcSEcCtD
Metoprolol—Weight increased—Capecitabine—esophageal cancer	0.000589	0.00409	CcSEcCtD
Metoprolol—Visual disturbance—Methotrexate—esophageal cancer	0.000588	0.00408	CcSEcCtD
Metoprolol—Muscle spasms—Cisplatin—esophageal cancer	0.000588	0.00408	CcSEcCtD
Metoprolol—Pneumonia—Capecitabine—esophageal cancer	0.00058	0.00403	CcSEcCtD
Metoprolol—Vision blurred—Cisplatin—esophageal cancer	0.000576	0.004	CcSEcCtD
Metoprolol—Depression—Capecitabine—esophageal cancer	0.000575	0.00399	CcSEcCtD
Metoprolol—Acebutolol—ABCB1—esophageal cancer	0.000574	0.153	CrCbGaD
Metoprolol—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000569	0.00395	CcSEcCtD
Metoprolol—Jaundice—Capecitabine—esophageal cancer	0.000562	0.0039	CcSEcCtD
Metoprolol—Conjunctivitis—Capecitabine—esophageal cancer	0.000561	0.00389	CcSEcCtD
Metoprolol—Leukopenia—Cisplatin—esophageal cancer	0.000547	0.0038	CcSEcCtD
Metoprolol—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000545	0.00379	CcSEcCtD
Metoprolol—Agranulocytosis—Capecitabine—esophageal cancer	0.000538	0.00374	CcSEcCtD
Metoprolol—Mood swings—Methotrexate—esophageal cancer	0.000528	0.00366	CcSEcCtD
Metoprolol—Bradycardia—Capecitabine—esophageal cancer	0.000527	0.00366	CcSEcCtD
Metoprolol—Rhinitis—Capecitabine—esophageal cancer	0.000519	0.0036	CcSEcCtD
Metoprolol—Anxiety—Cisplatin—esophageal cancer	0.000519	0.0036	CcSEcCtD
Metoprolol—Hepatitis—Capecitabine—esophageal cancer	0.000518	0.00359	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000517	0.00359	CcSEcCtD
Metoprolol—Liver function test abnormal—Methotrexate—esophageal cancer	0.000514	0.00357	CcSEcCtD
Metoprolol—Oedema peripheral—Capecitabine—esophageal cancer	0.00051	0.00354	CcSEcCtD
Metoprolol—Connective tissue disorder—Capecitabine—esophageal cancer	0.000509	0.00353	CcSEcCtD
Metoprolol—Breast disorder—Methotrexate—esophageal cancer	0.000503	0.00349	CcSEcCtD
Metoprolol—Oedema—Cisplatin—esophageal cancer	0.000499	0.00346	CcSEcCtD
Metoprolol—Visual impairment—Capecitabine—esophageal cancer	0.000499	0.00346	CcSEcCtD
Metoprolol—Nervous system disorder—Cisplatin—esophageal cancer	0.000489	0.0034	CcSEcCtD
Metoprolol—Thrombocytopenia—Cisplatin—esophageal cancer	0.000489	0.00339	CcSEcCtD
Metoprolol—Tachycardia—Cisplatin—esophageal cancer	0.000487	0.00338	CcSEcCtD
Metoprolol—Skin disorder—Cisplatin—esophageal cancer	0.000485	0.00336	CcSEcCtD
Metoprolol—Eye disorder—Capecitabine—esophageal cancer	0.000484	0.00336	CcSEcCtD
Metoprolol—Tinnitus—Capecitabine—esophageal cancer	0.000483	0.00335	CcSEcCtD
Metoprolol—Hyperhidrosis—Cisplatin—esophageal cancer	0.000482	0.00335	CcSEcCtD
Metoprolol—Cardiac disorder—Capecitabine—esophageal cancer	0.00048	0.00334	CcSEcCtD
Metoprolol—Angiopathy—Capecitabine—esophageal cancer	0.00047	0.00326	CcSEcCtD
Metoprolol—Immune system disorder—Capecitabine—esophageal cancer	0.000468	0.00325	CcSEcCtD
Metoprolol—Mediastinal disorder—Capecitabine—esophageal cancer	0.000467	0.00324	CcSEcCtD
Metoprolol—Hypotension—Cisplatin—esophageal cancer	0.000466	0.00324	CcSEcCtD
Metoprolol—Arrhythmia—Capecitabine—esophageal cancer	0.000462	0.00321	CcSEcCtD
Metoprolol—Alopecia—Capecitabine—esophageal cancer	0.000457	0.00318	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000455	0.00316	CcSEcCtD
Metoprolol—Mental disorder—Capecitabine—esophageal cancer	0.000454	0.00315	CcSEcCtD
Metoprolol—Paraesthesia—Cisplatin—esophageal cancer	0.000448	0.00311	CcSEcCtD
Metoprolol—Dyspnoea—Cisplatin—esophageal cancer	0.000445	0.00309	CcSEcCtD
Metoprolol—Flatulence—Capecitabine—esophageal cancer	0.000444	0.00308	CcSEcCtD
Metoprolol—Erectile dysfunction—Methotrexate—esophageal cancer	0.000443	0.00308	CcSEcCtD
Metoprolol—Dysgeusia—Capecitabine—esophageal cancer	0.000441	0.00306	CcSEcCtD
Metoprolol—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00044	0.00305	CcSEcCtD
Metoprolol—Muscle spasms—Capecitabine—esophageal cancer	0.000433	0.00301	CcSEcCtD
Metoprolol—Pneumonia—Methotrexate—esophageal cancer	0.000432	0.003	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000431	0.00299	CcSEcCtD
Metoprolol—Depression—Methotrexate—esophageal cancer	0.000428	0.00297	CcSEcCtD
Metoprolol—Pain—Cisplatin—esophageal cancer	0.000427	0.00296	CcSEcCtD
Metoprolol—Vision blurred—Capecitabine—esophageal cancer	0.000425	0.00295	CcSEcCtD
Metoprolol—Conjunctivitis—Methotrexate—esophageal cancer	0.000417	0.0029	CcSEcCtD
Metoprolol—Sweating—Methotrexate—esophageal cancer	0.000412	0.00286	CcSEcCtD
Metoprolol—Feeling abnormal—Cisplatin—esophageal cancer	0.000411	0.00285	CcSEcCtD
Metoprolol—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000406	0.00282	CcSEcCtD
Metoprolol—Vertigo—Capecitabine—esophageal cancer	0.000405	0.00281	CcSEcCtD
Metoprolol—Syncope—Capecitabine—esophageal cancer	0.000404	0.00281	CcSEcCtD
Metoprolol—Leukopenia—Capecitabine—esophageal cancer	0.000403	0.0028	CcSEcCtD
Metoprolol—Agranulocytosis—Methotrexate—esophageal cancer	0.000401	0.00278	CcSEcCtD
Metoprolol—Palpitations—Capecitabine—esophageal cancer	0.000398	0.00276	CcSEcCtD
Metoprolol—Loss of consciousness—Capecitabine—esophageal cancer	0.000396	0.00275	CcSEcCtD
Metoprolol—Body temperature increased—Cisplatin—esophageal cancer	0.000394	0.00274	CcSEcCtD
Metoprolol—Hypertension—Capecitabine—esophageal cancer	0.000389	0.0027	CcSEcCtD
Metoprolol—Hepatitis—Methotrexate—esophageal cancer	0.000385	0.00268	CcSEcCtD
Metoprolol—Arthralgia—Capecitabine—esophageal cancer	0.000384	0.00266	CcSEcCtD
Metoprolol—Chest pain—Capecitabine—esophageal cancer	0.000384	0.00266	CcSEcCtD
Metoprolol—Anxiety—Capecitabine—esophageal cancer	0.000382	0.00265	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000381	0.00265	CcSEcCtD
Metoprolol—Dry mouth—Capecitabine—esophageal cancer	0.000375	0.0026	CcSEcCtD
Metoprolol—Visual impairment—Methotrexate—esophageal cancer	0.000371	0.00258	CcSEcCtD
Metoprolol—Confusional state—Capecitabine—esophageal cancer	0.000371	0.00257	CcSEcCtD
Metoprolol—Oedema—Capecitabine—esophageal cancer	0.000368	0.00255	CcSEcCtD
Metoprolol—Hypersensitivity—Cisplatin—esophageal cancer	0.000368	0.00255	CcSEcCtD
Metoprolol—Shock—Capecitabine—esophageal cancer	0.000362	0.00251	CcSEcCtD
Metoprolol—Nervous system disorder—Capecitabine—esophageal cancer	0.000361	0.0025	CcSEcCtD
Metoprolol—Eye disorder—Methotrexate—esophageal cancer	0.00036	0.0025	CcSEcCtD
Metoprolol—Thrombocytopenia—Capecitabine—esophageal cancer	0.00036	0.0025	CcSEcCtD
Metoprolol—Tinnitus—Methotrexate—esophageal cancer	0.000359	0.00249	CcSEcCtD
Metoprolol—Tachycardia—Capecitabine—esophageal cancer	0.000359	0.00249	CcSEcCtD
Metoprolol—Asthenia—Cisplatin—esophageal cancer	0.000358	0.00249	CcSEcCtD
Metoprolol—Cardiac disorder—Methotrexate—esophageal cancer	0.000358	0.00248	CcSEcCtD
Metoprolol—Skin disorder—Capecitabine—esophageal cancer	0.000357	0.00248	CcSEcCtD
Metoprolol—Hyperhidrosis—Capecitabine—esophageal cancer	0.000356	0.00247	CcSEcCtD
Metoprolol—Angiopathy—Methotrexate—esophageal cancer	0.00035	0.00243	CcSEcCtD
Metoprolol—Immune system disorder—Methotrexate—esophageal cancer	0.000348	0.00242	CcSEcCtD
Metoprolol—Mediastinal disorder—Methotrexate—esophageal cancer	0.000347	0.00241	CcSEcCtD
Metoprolol—Hypotension—Capecitabine—esophageal cancer	0.000344	0.00239	CcSEcCtD
Metoprolol—Diarrhoea—Cisplatin—esophageal cancer	0.000341	0.00237	CcSEcCtD
Metoprolol—Alopecia—Methotrexate—esophageal cancer	0.000341	0.00236	CcSEcCtD
Metoprolol—Mental disorder—Methotrexate—esophageal cancer	0.000338	0.00234	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000335	0.00233	CcSEcCtD
Metoprolol—Insomnia—Capecitabine—esophageal cancer	0.000333	0.00231	CcSEcCtD
Metoprolol—Paraesthesia—Capecitabine—esophageal cancer	0.00033	0.00229	CcSEcCtD
Metoprolol—Dysgeusia—Methotrexate—esophageal cancer	0.000329	0.00228	CcSEcCtD
Metoprolol—Dyspnoea—Capecitabine—esophageal cancer	0.000328	0.00228	CcSEcCtD
Metoprolol—Dyspepsia—Capecitabine—esophageal cancer	0.000324	0.00225	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000318	0.0022	CcSEcCtD
Metoprolol—Vomiting—Cisplatin—esophageal cancer	0.000317	0.0022	CcSEcCtD
Metoprolol—Fatigue—Capecitabine—esophageal cancer	0.000317	0.0022	CcSEcCtD
Metoprolol—Vision blurred—Methotrexate—esophageal cancer	0.000316	0.00219	CcSEcCtD
Metoprolol—Rash—Cisplatin—esophageal cancer	0.000315	0.00218	CcSEcCtD
Metoprolol—Constipation—Capecitabine—esophageal cancer	0.000315	0.00218	CcSEcCtD
Metoprolol—Pain—Capecitabine—esophageal cancer	0.000315	0.00218	CcSEcCtD
Metoprolol—Dermatitis—Cisplatin—esophageal cancer	0.000314	0.00218	CcSEcCtD
Metoprolol—Feeling abnormal—Capecitabine—esophageal cancer	0.000303	0.0021	CcSEcCtD
Metoprolol—Vertigo—Methotrexate—esophageal cancer	0.000301	0.00209	CcSEcCtD
Metoprolol—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000301	0.00209	CcSEcCtD
Metoprolol—Leukopenia—Methotrexate—esophageal cancer	0.0003	0.00208	CcSEcCtD
Metoprolol—Nausea—Cisplatin—esophageal cancer	0.000296	0.00206	CcSEcCtD
Metoprolol—Urticaria—Capecitabine—esophageal cancer	0.000292	0.00203	CcSEcCtD
Metoprolol—Abdominal pain—Capecitabine—esophageal cancer	0.000291	0.00202	CcSEcCtD
Metoprolol—Body temperature increased—Capecitabine—esophageal cancer	0.000291	0.00202	CcSEcCtD
Metoprolol—Chest pain—Methotrexate—esophageal cancer	0.000286	0.00198	CcSEcCtD
Metoprolol—Arthralgia—Methotrexate—esophageal cancer	0.000286	0.00198	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000284	0.00197	CcSEcCtD
Metoprolol—Confusional state—Methotrexate—esophageal cancer	0.000276	0.00192	CcSEcCtD
Metoprolol—Hypersensitivity—Capecitabine—esophageal cancer	0.000271	0.00188	CcSEcCtD
Metoprolol—Nervous system disorder—Methotrexate—esophageal cancer	0.000269	0.00186	CcSEcCtD
Metoprolol—Thrombocytopenia—Methotrexate—esophageal cancer	0.000268	0.00186	CcSEcCtD
Metoprolol—Skin disorder—Methotrexate—esophageal cancer	0.000266	0.00185	CcSEcCtD
Metoprolol—Hyperhidrosis—Methotrexate—esophageal cancer	0.000265	0.00184	CcSEcCtD
Metoprolol—Asthenia—Capecitabine—esophageal cancer	0.000264	0.00183	CcSEcCtD
Metoprolol—Pruritus—Capecitabine—esophageal cancer	0.00026	0.00181	CcSEcCtD
Metoprolol—Hypotension—Methotrexate—esophageal cancer	0.000256	0.00178	CcSEcCtD
Metoprolol—Diarrhoea—Capecitabine—esophageal cancer	0.000252	0.00175	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000249	0.00173	CcSEcCtD
Metoprolol—Insomnia—Methotrexate—esophageal cancer	0.000248	0.00172	CcSEcCtD
Metoprolol—Paraesthesia—Methotrexate—esophageal cancer	0.000246	0.00171	CcSEcCtD
Metoprolol—Propranolol—ABCB1—esophageal cancer	0.000245	0.065	CrCbGaD
Metoprolol—Dyspnoea—Methotrexate—esophageal cancer	0.000244	0.00169	CcSEcCtD
Metoprolol—Somnolence—Methotrexate—esophageal cancer	0.000243	0.00169	CcSEcCtD
Metoprolol—Dizziness—Capecitabine—esophageal cancer	0.000243	0.00169	CcSEcCtD
Metoprolol—Dyspepsia—Methotrexate—esophageal cancer	0.000241	0.00167	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000236	0.00164	CcSEcCtD
Metoprolol—Fatigue—Methotrexate—esophageal cancer	0.000236	0.00164	CcSEcCtD
Metoprolol—Pain—Methotrexate—esophageal cancer	0.000234	0.00163	CcSEcCtD
Metoprolol—Vomiting—Capecitabine—esophageal cancer	0.000234	0.00162	CcSEcCtD
Metoprolol—Rash—Capecitabine—esophageal cancer	0.000232	0.00161	CcSEcCtD
Metoprolol—Dermatitis—Capecitabine—esophageal cancer	0.000232	0.00161	CcSEcCtD
Metoprolol—Headache—Capecitabine—esophageal cancer	0.00023	0.0016	CcSEcCtD
Metoprolol—Feeling abnormal—Methotrexate—esophageal cancer	0.000226	0.00157	CcSEcCtD
Metoprolol—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000224	0.00155	CcSEcCtD
Metoprolol—Nausea—Capecitabine—esophageal cancer	0.000218	0.00152	CcSEcCtD
Metoprolol—Urticaria—Methotrexate—esophageal cancer	0.000218	0.00151	CcSEcCtD
Metoprolol—Abdominal pain—Methotrexate—esophageal cancer	0.000216	0.0015	CcSEcCtD
Metoprolol—Body temperature increased—Methotrexate—esophageal cancer	0.000216	0.0015	CcSEcCtD
Metoprolol—Hypersensitivity—Methotrexate—esophageal cancer	0.000202	0.0014	CcSEcCtD
Metoprolol—Asthenia—Methotrexate—esophageal cancer	0.000196	0.00136	CcSEcCtD
Metoprolol—Pruritus—Methotrexate—esophageal cancer	0.000194	0.00134	CcSEcCtD
Metoprolol—Diarrhoea—Methotrexate—esophageal cancer	0.000187	0.0013	CcSEcCtD
Metoprolol—Dizziness—Methotrexate—esophageal cancer	0.000181	0.00126	CcSEcCtD
Metoprolol—Vomiting—Methotrexate—esophageal cancer	0.000174	0.00121	CcSEcCtD
Metoprolol—Rash—Methotrexate—esophageal cancer	0.000173	0.0012	CcSEcCtD
Metoprolol—Dermatitis—Methotrexate—esophageal cancer	0.000172	0.0012	CcSEcCtD
Metoprolol—Headache—Methotrexate—esophageal cancer	0.000172	0.00119	CcSEcCtD
Metoprolol—Nausea—Methotrexate—esophageal cancer	0.000163	0.00113	CcSEcCtD
Metoprolol—SLC22A2—Metabolism—ADH7—esophageal cancer	7.31e-05	0.000915	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PLCE1—esophageal cancer	7.31e-05	0.000915	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	7.3e-05	0.000914	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—GNG7—esophageal cancer	7.17e-05	0.000898	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—GNG7—esophageal cancer	7.02e-05	0.000878	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—CXCL2—esophageal cancer	6.96e-05	0.000871	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—WWOX—esophageal cancer	6.91e-05	0.000865	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—CXCL2—esophageal cancer	6.81e-05	0.000852	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—WWOX—esophageal cancer	6.76e-05	0.000846	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—FKBP1A—esophageal cancer	6.57e-05	0.000823	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—ANXA1—esophageal cancer	6.47e-05	0.00081	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—FKBP1A—esophageal cancer	6.43e-05	0.000805	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—WIF1—esophageal cancer	6.43e-05	0.000804	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—ADH1B—esophageal cancer	6.41e-05	0.000803	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	6.37e-05	0.000797	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—ANXA1—esophageal cancer	6.33e-05	0.000792	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—CXCL2—esophageal cancer	6.32e-05	0.000791	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—SST—esophageal cancer	6.29e-05	0.000788	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—WIF1—esophageal cancer	6.29e-05	0.000787	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	6.27e-05	0.000785	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	6.2e-05	0.000776	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—CXCL2—esophageal cancer	6.18e-05	0.000774	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—SST—esophageal cancer	6.16e-05	0.00077	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—GHRL—esophageal cancer	6.13e-05	0.000767	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—TYMP—esophageal cancer	6.13e-05	0.000767	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	6.02e-05	0.000753	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—GHRL—esophageal cancer	6e-05	0.000751	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CYP26A1—esophageal cancer	5.96e-05	0.000746	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CSNK1A1—esophageal cancer	5.93e-05	0.000742	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—ANXA1—esophageal cancer	5.87e-05	0.000735	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—ALOX15—esophageal cancer	5.81e-05	0.000727	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CSNK1A1—esophageal cancer	5.8e-05	0.000726	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—ANXA1—esophageal cancer	5.75e-05	0.000719	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—SST—esophageal cancer	5.71e-05	0.000715	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—SLC52A3—esophageal cancer	5.66e-05	0.000709	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—BLVRB—esophageal cancer	5.66e-05	0.000709	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	5.62e-05	0.000704	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—SST—esophageal cancer	5.59e-05	0.0007	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—GHRL—esophageal cancer	5.57e-05	0.000697	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	5.56e-05	0.000696	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PFN1—esophageal cancer	5.55e-05	0.000694	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GSTO1—esophageal cancer	5.54e-05	0.000694	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—TPI1—esophageal cancer	5.54e-05	0.000694	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	5.54e-05	0.000693	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—SLC52A3—esophageal cancer	5.53e-05	0.000692	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—BLVRB—esophageal cancer	5.53e-05	0.000692	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—GHRL—esophageal cancer	5.45e-05	0.000682	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PFN1—esophageal cancer	5.43e-05	0.000679	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—ALDOB—esophageal cancer	5.31e-05	0.000665	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—BLVRB—esophageal cancer	5.21e-05	0.000652	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—SLC52A3—esophageal cancer	5.21e-05	0.000652	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GAPDH—esophageal cancer	5.11e-05	0.00064	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CRABP1—esophageal cancer	5.07e-05	0.000634	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	5.06e-05	0.000633	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ELMO1—esophageal cancer	4.98e-05	0.000624	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ELMO1—esophageal cancer	4.87e-05	0.00061	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—AKAP13—esophageal cancer	4.87e-05	0.00061	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GNG7—esophageal cancer	4.82e-05	0.000603	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—SLC10A2—esophageal cancer	4.81e-05	0.000602	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CA1—esophageal cancer	4.81e-05	0.000602	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	4.77e-05	0.000597	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—AKAP13—esophageal cancer	4.76e-05	0.000596	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CA1—esophageal cancer	4.7e-05	0.000588	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—SLC10A2—esophageal cancer	4.7e-05	0.000588	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	4.64e-05	0.00058	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	4.53e-05	0.000567	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—ALDH2—esophageal cancer	4.52e-05	0.000565	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HIST1H2BM—esophageal cancer	4.49e-05	0.000562	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PDE4D—esophageal cancer	4.45e-05	0.000557	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CA1—esophageal cancer	4.43e-05	0.000554	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—SLC10A2—esophageal cancer	4.43e-05	0.000554	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CA2—esophageal cancer	4.4e-05	0.000551	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HIST1H2BM—esophageal cancer	4.4e-05	0.00055	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PDE4D—esophageal cancer	4.36e-05	0.000545	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	4.3e-05	0.000539	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CA2—esophageal cancer	4.3e-05	0.000538	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GSTT1—esophageal cancer	4.3e-05	0.000538	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CYP2A6—esophageal cancer	4.25e-05	0.000532	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—GNG7—esophageal cancer	4.24e-05	0.00053	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—GNG7—esophageal cancer	4.14e-05	0.000519	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	4.1e-05	0.000513	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PLCE1—esophageal cancer	4.09e-05	0.000512	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ADH7—esophageal cancer	4.09e-05	0.000512	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CA2—esophageal cancer	4.05e-05	0.000507	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.05e-05	0.000506	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—ENO1—esophageal cancer	4.03e-05	0.000504	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PTGS1—esophageal cancer	4.03e-05	0.000504	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	4.02e-05	0.000504	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PLCE1—esophageal cancer	4e-05	0.0005	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ADH7—esophageal cancer	4e-05	0.0005	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—XIAP—esophageal cancer	3.97e-05	0.000497	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PSME1—esophageal cancer	3.97e-05	0.000497	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PSME2—esophageal cancer	3.97e-05	0.000497	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	3.96e-05	0.000496	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—XIAP—esophageal cancer	3.88e-05	0.000486	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	3.77e-05	0.000472	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ADH7—esophageal cancer	3.76e-05	0.000471	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PLCE1—esophageal cancer	3.76e-05	0.000471	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CTNNA1—esophageal cancer	3.75e-05	0.00047	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CXCL2—esophageal cancer	3.73e-05	0.000467	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CTNNA1—esophageal cancer	3.67e-05	0.00046	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CXCL2—esophageal cancer	3.65e-05	0.000457	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ADH1B—esophageal cancer	3.59e-05	0.000449	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ADH1B—esophageal cancer	3.5e-05	0.000438	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PSME2—esophageal cancer	3.49e-05	0.000436	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PSME1—esophageal cancer	3.49e-05	0.000436	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ANXA1—esophageal cancer	3.47e-05	0.000434	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—TYMP—esophageal cancer	3.43e-05	0.000429	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	3.43e-05	0.000429	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CYP1B1—esophageal cancer	3.42e-05	0.000429	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PSME1—esophageal cancer	3.41e-05	0.000427	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PSME2—esophageal cancer	3.41e-05	0.000427	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ANXA1—esophageal cancer	3.39e-05	0.000425	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—SST—esophageal cancer	3.38e-05	0.000422	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—TYMP—esophageal cancer	3.35e-05	0.000419	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CYP26A1—esophageal cancer	3.34e-05	0.000418	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SST—esophageal cancer	3.3e-05	0.000413	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ADH1B—esophageal cancer	3.3e-05	0.000413	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NOTCH3—esophageal cancer	3.29e-05	0.000412	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—GHRL—esophageal cancer	3.29e-05	0.000412	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	3.29e-05	0.000411	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYP26A1—esophageal cancer	3.26e-05	0.000408	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ALOX15—esophageal cancer	3.25e-05	0.000407	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—FBXW7—esophageal cancer	3.24e-05	0.000405	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CYP19A1—esophageal cancer	3.22e-05	0.000403	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NOTCH3—esophageal cancer	3.22e-05	0.000403	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—GHRL—esophageal cancer	3.22e-05	0.000403	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.21e-05	0.000402	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ALOX15—esophageal cancer	3.17e-05	0.000397	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—FBXW7—esophageal cancer	3.17e-05	0.000396	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—TYMP—esophageal cancer	3.15e-05	0.000395	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—TPI1—esophageal cancer	3.1e-05	0.000388	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTO1—esophageal cancer	3.1e-05	0.000388	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYP26A1—esophageal cancer	3.07e-05	0.000384	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—TPI1—esophageal cancer	3.03e-05	0.000379	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTO1—esophageal cancer	3.03e-05	0.000379	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ALOX15—esophageal cancer	2.99e-05	0.000374	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ALDOB—esophageal cancer	2.97e-05	0.000372	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NOTCH2—esophageal cancer	2.95e-05	0.000369	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—HMOX1—esophageal cancer	2.94e-05	0.000368	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ALDOB—esophageal cancer	2.9e-05	0.000363	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NOTCH2—esophageal cancer	2.89e-05	0.000361	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GAPDH—esophageal cancer	2.86e-05	0.000358	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTO1—esophageal cancer	2.85e-05	0.000357	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—TPI1—esophageal cancer	2.85e-05	0.000357	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CRABP1—esophageal cancer	2.84e-05	0.000355	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—ABCB1—esophageal cancer	2.82e-05	0.000353	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GAPDH—esophageal cancer	2.79e-05	0.00035	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.79e-05	0.000349	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CRABP1—esophageal cancer	2.77e-05	0.000347	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ALDOB—esophageal cancer	2.74e-05	0.000342	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GNG7—esophageal cancer	2.7e-05	0.000338	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.7e-05	0.000338	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GNG7—esophageal cancer	2.63e-05	0.00033	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GAPDH—esophageal cancer	2.63e-05	0.00033	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TGFBR2—esophageal cancer	2.62e-05	0.000328	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CRABP1—esophageal cancer	2.61e-05	0.000327	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TGFBR2—esophageal cancer	2.56e-05	0.00032	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ALDH2—esophageal cancer	2.53e-05	0.000316	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GNG7—esophageal cancer	2.48e-05	0.000311	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—SMAD4—esophageal cancer	2.48e-05	0.00031	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ALDH2—esophageal cancer	2.47e-05	0.000309	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SMAD4—esophageal cancer	2.42e-05	0.000303	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTT1—esophageal cancer	2.41e-05	0.000301	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CYP2A6—esophageal cancer	2.38e-05	0.000298	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.37e-05	0.000296	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTT1—esophageal cancer	2.35e-05	0.000294	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ALDH2—esophageal cancer	2.33e-05	0.000291	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.32e-05	0.00029	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ENO1—esophageal cancer	2.25e-05	0.000282	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PTGS1—esophageal cancer	2.25e-05	0.000282	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PSME1—esophageal cancer	2.22e-05	0.000278	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PSME2—esophageal cancer	2.22e-05	0.000278	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTT1—esophageal cancer	2.21e-05	0.000277	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ENO1—esophageal cancer	2.2e-05	0.000275	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PTGS1—esophageal cancer	2.2e-05	0.000275	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.2e-05	0.000275	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYP2A6—esophageal cancer	2.19e-05	0.000274	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PSME2—esophageal cancer	2.17e-05	0.000271	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PSME1—esophageal cancer	2.17e-05	0.000271	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ENO1—esophageal cancer	2.07e-05	0.000259	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PTGS1—esophageal cancer	2.07e-05	0.000259	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PSME2—esophageal cancer	2.04e-05	0.000256	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PSME1—esophageal cancer	2.04e-05	0.000256	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HIF1A—esophageal cancer	2.03e-05	0.000254	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HIF1A—esophageal cancer	1.98e-05	0.000248	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.94e-05	0.000243	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—KDR—esophageal cancer	1.94e-05	0.000243	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CYP1B1—esophageal cancer	1.92e-05	0.00024	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—KDR—esophageal cancer	1.9e-05	0.000237	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CREBBP—esophageal cancer	1.88e-05	0.000236	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.87e-05	0.000234	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NOTCH1—esophageal cancer	1.83e-05	0.000229	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CYP19A1—esophageal cancer	1.8e-05	0.000226	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NOTCH1—esophageal cancer	1.79e-05	0.000224	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYP1B1—esophageal cancer	1.76e-05	0.000221	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.76e-05	0.00022	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—NOS3—esophageal cancer	1.69e-05	0.000211	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYP19A1—esophageal cancer	1.66e-05	0.000207	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CREBBP—esophageal cancer	1.66e-05	0.000207	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—HMOX1—esophageal cancer	1.64e-05	0.000206	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—EGFR—esophageal cancer	1.63e-05	0.000204	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CREBBP—esophageal cancer	1.62e-05	0.000203	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.61e-05	0.000202	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—HMOX1—esophageal cancer	1.6e-05	0.000201	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—EGFR—esophageal cancer	1.59e-05	0.000199	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ABCB1—esophageal cancer	1.58e-05	0.000198	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.56e-05	0.000195	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PTGS2—esophageal cancer	1.54e-05	0.000193	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.52e-05	0.00019	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.51e-05	0.000189	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—NOS3—esophageal cancer	1.48e-05	0.000186	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.45e-05	0.000182	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—NOS3—esophageal cancer	1.45e-05	0.000182	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PIK3CA—esophageal cancer	1.41e-05	0.000177	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	1.39e-05	0.000174	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PIK3CA—esophageal cancer	1.38e-05	0.000173	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ERBB2—esophageal cancer	1.36e-05	0.00017	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—EP300—esophageal cancer	1.28e-05	0.000161	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CCND1—esophageal cancer	1.23e-05	0.000153	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CCND1—esophageal cancer	1.2e-05	0.00015	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.19e-05	0.000149	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	1.19e-05	0.000148	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CDKN1A—esophageal cancer	1.16e-05	0.000145	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—EP300—esophageal cancer	1.13e-05	0.000141	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—EP300—esophageal cancer	1.1e-05	0.000138	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CREBBP—esophageal cancer	1.05e-05	0.000132	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CREBBP—esophageal cancer	1.03e-05	0.000129	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MYC—esophageal cancer	9.83e-06	0.000123	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CREBBP—esophageal cancer	9.7e-06	0.000121	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MYC—esophageal cancer	9.61e-06	0.00012	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—EGFR—esophageal cancer	9.61e-06	0.00012	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CA—esophageal cancer	9.49e-06	0.000119	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—NOS3—esophageal cancer	9.44e-06	0.000118	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—EGFR—esophageal cancer	9.4e-06	0.000118	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NOS3—esophageal cancer	9.22e-06	0.000115	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NOS3—esophageal cancer	8.69e-06	0.000109	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PTGS2—esophageal cancer	8.64e-06	0.000108	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PTGS2—esophageal cancer	8.43e-06	0.000106	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	8.34e-06	0.000104	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CA—esophageal cancer	8.16e-06	0.000102	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TP53—esophageal cancer	8.07e-06	0.000101	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PTGS2—esophageal cancer	7.94e-06	9.94e-05	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TP53—esophageal cancer	7.89e-06	9.88e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—EP300—esophageal cancer	7.18e-06	8.99e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—EP300—esophageal cancer	7.01e-06	8.78e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—EP300—esophageal cancer	6.61e-06	8.27e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CA—esophageal cancer	5.31e-06	6.65e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CA—esophageal cancer	5.19e-06	6.49e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CA—esophageal cancer	4.89e-06	6.12e-05	CbGpPWpGaD
